Abstract: Glucocorticoids and other immunosuppressants are the primary therapeutic options for non-infectious uveitis. Novel biodegradable sustained-release vitreous implants are promising for extensive clinical applications, and biological agents have shown unique efficacy. The currently applied topical glucocorticoid implants include fluocinolone acetonide implant, dexamethasone vitreous implant, etc. The immunosuppressants include antimetabolites methotrexate, azathioprine, and mycophenolate mofetil, etc.; T cell inhibitors cyclosporine, tacrolimus, and rapamycin, etc.; and alkylating agents cyclophosphamide and chlorambucil, etc. The biological agents include anti-tumor necrosis factor agents infliximab, adalimumab, etanercept, golimumab, and certolizumab, etc.; interleukin receptor antagonists anakinra, canalizumab, and tocilizumab, etc.; selective B lymphocyte inhibitor rituximab; and selective T lymphocyte inhibitor abatacept, etc. Different agents have their respective scopes of application and adverse reactions. It is particularly important to select a treatment regimen appropriate for the patient’s condition, to control disease progression, and to reduce complications.(Int Rev Ophthalmol, 2021, 45: 89-98)

Key words: non-infectious uveitis, corticosteroid implant, immunosuppressor, biologic agent